Assessment of Sclerostin and Interleukin 6 Levels and Selected Anthropometric Parameters in Patients Receiving Hemodialysis Replacement Therapy—Pilot Study
by
Agnieszka Turon-Skrzypinska 1,*, Grazyna Dutkiewicz 2, Malgorzata Marchelek-Mysliwiec 2, Violetta Dziedziejko 3, Kazimierz Ciechanowski 2, Aleksandra Ryl 1
and Iwona Rotter 1
Agnieszka Turon-Skrzypinska 1,*, Grazyna Dutkiewicz 2, Malgorzata Marchelek-Mysliwiec 2, Violetta Dziedziejko 3, Kazimierz Ciechanowski 2, Aleksandra Ryl 1 and Iwona Rotter 1
1
Department of Medical Rehabilitation and Clinical Rehabilitation, Pomeranian Medical University, 71-210 Szczecin, Poland
2
Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, 70-111Szczecin, Poland
3
Department of Biochemistry and Medical Chemistry, Pomeranian Medical University, 70-111 Szczecin, Poland
*
Author to whom correspondence should be addressed.
Medicina 2019, 55(12), 784; https://doi.org/10.3390/medicina55120784
Received: 7 November 2019 / Revised: 3 December 2019 / Accepted: 11 December 2019 / Published: 15 December 2019
Background and Objectives: Chronic kidney disease (CKD) is an important public health problem associated with, e.g., progressive renal insufficiency, bone mineral disorders, and increased inflammatory marker levels. The objective of this study was to compare selected biochemical parameters and to evaluate potential correlations between selected anthropometric parameters and levels of sclerostin and interleukin 6 (IL-6) in blood plasma. Materials and Methods: The study group consisted of 34 patients aged 59.8 ± 9.8 years, receiving hemodialysis therapy. The control group consisted of 31 individuals aged 55.4 ± 9.37 years, presenting with GFR (glomerular filtration rate) of more than 60 mL/min/1.73 m2. Selected anthropometric and biochemical parameters were assessed at baseline, as well as 3 and 6 months into the study. Statistical analyses were performed using the Statistica 2014 software package (StatSoft, Inc.Tulsa, OK, USA). Analyses included descriptive statistics, intergroup comparisons using the Mann-Whitney U-test or the Kruskal-Wallis test, and Spearman’s correlation analysis. The significance level was set at p ≤ 0.005. Results: At all measurement time points, i.e., at baseline, at month 3, and at month 6, the IL-6 levels in the study group were significantly higher than those in the control group. No correlations were observed in the study group between SCL or IL-6 levels and anthropometric parameters such as body weight, body mass index (BMI), or waist circumference. Conclusions: Patients receiving hemodialysis replacement therapy present with significantly higher levels of IL-6 in their blood. Anthropometric parameters (body weight, BMI, and waist circumference) have no impact on sclerostin and IL-6 levels in patients undergoing hemodialysis therapy. The results obtained are satisfactory, and the research will be continued.
View Full-Text
Keywords:
chronic kidney disease; sclerostin level in hemodialysis patients; interleukin 6 level in hemodialysis patients; anthropometric parameters
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Turon-Skrzypinska, A.; Dutkiewicz, G.; Marchelek-Mysliwiec, M.; Dziedziejko, V.; Ciechanowski, K.; Ryl, A.; Rotter, I. Assessment of Sclerostin and Interleukin 6 Levels and Selected Anthropometric Parameters in Patients Receiving Hemodialysis Replacement Therapy—Pilot Study. Medicina 2019, 55, 784.
Show more citation formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
